Title : The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.

Pub. Date : 2004 Nov

PMID : 15537471






7 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Insulin glargine, a long-acting insulin, has shown benefits of decreased nocturnal hypoglycemia without significant weight gain, while providing good glycemic control in clinical trials. Insulin Glargine insulin Homo sapiens
2 Insulin glargine, a long-acting insulin, has shown benefits of decreased nocturnal hypoglycemia without significant weight gain, while providing good glycemic control in clinical trials. Insulin Glargine insulin Homo sapiens
3 The objective of this study was to evaluate the effectiveness of insulin glargine over a 12-month period in a clinical practice setting, and measure its effects on HRQOL in a subset of patients. Insulin Glargine insulin Homo sapiens
4 DESIGN AND METHODS: Patients with diabetes in a large private endocrinology practice were initiated on insulin glargine. Insulin Glargine insulin Homo sapiens
5 In the year following insulin glargine therapy, there were significantly fewer hypoglycemic events per patient than in the year prior to insulin glargine therapy (group T1D: -0.33, P = 0.002; group T2D: -0.20, P = 0.004). Insulin Glargine insulin Homo sapiens
6 HRQOL subset analysis also revealed a significant decrease in A1C (P < 0.0001) after 16 weeks of therapy with insulin glargine. Insulin Glargine insulin Homo sapiens
7 CONCLUSIONS: Insulin glargine use over a 12-month period in a clinical practice setting was shown to significantly improve A1C without adversely impacting weight or the occurrence of hypoglycemia. Insulin Glargine insulin Homo sapiens